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Summary. Pharmacokinetic profiles were determined in 
seven healthy young male subjects following single oral 
and intravenous doses of 10 mg of yohimbine hydro- 
chloride. 
The drug was rapidly eliminated (tle~ 0.58 h orally and 
tin[3 0.68 h intravenously). Following intravenous adminis- 
tration the data fit a two-compartment pharmacokinetic 
model, with a very rapid distribution phase (tl/2a was ap- 
proximately 6 min). Both the oral and the intravenous 
yohimbine clearance values were high but oral clearance 
values were much higher (mean 9.77 ml. min 1. kg-1 in- 
travenous versus 55.9ml .min 1.kg 1 oral). The oral 
bioavailability showed great variability, ranging from 7% 
to 87% (mean value was 33%). 
The imcomplete oral bioavailability of yohimbine may 
reflect either incomplete absorption from the gastrointes- 
tinal tract or an hepatic first pass effect. Although yohim- 
bine is rapidly absorbed when given orally, the bioavaila- 
bility is quite variable and considerable individualization 
of dosing may be necessary when the drug is used orally 
for clinical indications. 
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Yohimbine is an indole alkaloid of botanical origin that 
has alpha2 adrenoceptor  blocking activity and has been 
extensively used for many years in folk medicine. Recent- 
ly it has also been increasingly used by the medical estab- 
lishment, most commonly in the treatment of male im- 
potence, an indication where it appears to show some 
promise [1, 2]. Additionally, it has some efficacy in the 
treatment of orthostatic hypotension, both idiosyncratic 
and drug-induced [3, 4]. 
Yohimbine exhibits an interesting variety of pharma- 
cologic and psychologic effects. Its alpha2 adrenoceptor  
blocking action results in an interruption of the norepine- 
phrine (NE) feedback inhibition loop resulting in a de- 
crease in the release of NE when autoreceptors are stimu- 
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lated [5, 6]. Consequently yohimbine administration may 
result ifi increases in blood pressure and heart rate as well 
as anxiety. The degree and type of response to yohimbine 
may be related to specific pathophysiology. Increments in 
blood pressure following yohimbine are more pro- 
nounced in patients with essential hypertension than in 
controls [7]. Additionally, in persons who suffer from 
panic disorder, or major depression with panic attacks, ad- 
ministration of yohimbine often results in the onset of a 
panic attack which is indistinguishable from a normally 
occurring panic attack [8, 9]. 
Although the physiological and psychological effects 
of yohimbine have been studied, little pharmacokinetic 
research has been conducted. Owen et al. [10] have con- 
ducted a detailed investigation of yohimbine pharmaco- 
kinetics in humans but they were not able to assess oral 
bioavailability due to the unavailability of an intravenous 
form of the drug. Oral bioavailability is an important con- 
sideration since yohimbine is most often administered 
orally. To determine the oral bioavailability of yohimbine 
we have administered a single dose of both oral and in- 
travenous yohimbine to seven healthy male volunteers. 
Materials, methods, and subjects studied 
Seven males, aged 21 to 36 y (mean 28.0 (6.7) y), were recruited by 
public announcement. All volunteers gave informed consent to par- 
ticipate. Subjects underwent a complete physical examination in- 
cluding blood and urine analyses, as well as an EKG. None of the 
subjects had any history of hypertension or other cardiovascular dis- 
ease. No abnormalities were found on laboratory or EKG pre- 
screening. None of the subjects were receiving medication and all ab- 
stained from any alcoholic beverage for 72 h prior to the study. 
On the evening prior to each of the two study sessions the volun- 
teers were admitted to the Clinical Research Center at the Univer- 
sity of Michigan Hospitals. They fasted from the midnight preceding 
the procedure until three hours following the administration of 
yohimbine. Ten mg of yohimbine hydrochloride solution (9.07 mg 
free base) was administered either intravenously or orally during 
each of the two studies. The order in which the subject received the 
oral and intravenous doses was randomized and the two study ses- 
sions were separated by at least i week. Five ml of blood was drawn 
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Fig. 1. Time versus plasma concentration curves for two subjects fol- 
lowing both oral ( [ ] )  and intravenous ( • )  doses of yohimbine. 
f = fraction of dose bioavailable when taken orally 
240 min following the oral or intravenous yohimbine dose. All blood 
samples were centrifuged and plasma was separated and stored at 
- 20°C until assayed. Blood pressure and heart rate were recorded in 
the lying position, at each blood draw time point using Air Shields 
(Healthdyne Co., Hatboro, PA) sphygmomanometers, which pro- 
vided printed output. 
Yohimbine plasma concentrations were determined using a 
newly developed high performance liquid chromatography cou- 
lometric electrochemical detector (Model 5100A, Environmental 
Assoc, Bedford, MA) method [11]. The analytical cell (Model 5010) 
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of the detector was set at a voltage of 0.8. A 5 gin, C-8 "DB" column 
(25 X 0.46 cm, Supelco, Bellefonte, PA) was used. The mobile phase 
consisted of water and acetonitrile 65 : 35 (V/V) containing 1.8 g of 
tetraethylammonium perchlorate per liter of solution, and the flow 
rate was 2.0 ml- rain- 7. Reserpiline was used as the internal standard. 
Both yohimbine and the internal standard were extracted from 1 ml 
of alkalinized plasma using n-butylchloride and purified by back ex- 
traction in perchloric acid. The sensitivity of the assay was 100 pg 
using i ml of plasma. The mean interassay coefficient of variation 
was 6%, recovery was 94% and the assay is linear from 0 to 
1000 ng. ml. 
The NONLIN computer program was utilized to determine the 
rate constants; c~, [3, and k,, as well as the volume of distribution (V~), 
and the constants, A and B [12]. The area under the plasma concen- 
tration versus time curve (AUC) was calculated using the trapezoi- 
dal method, the terminal portion of the area was determined using 
C,/[~ [13]. Both oral (CLpo) and intravenous clearances (CLi~) were 
calculated using dose/AUC. Bioavailability (f) was determined by 
comparing the AUCpo/AUC~v. Statistical analysis was performed 
using on an Apple Macintosh personal computer using the Statview 
statistical program [13]. 
Results  
Both the oral and intravenous data revealed a large 
amount of interindividual variability in yohimbine phar- 
macokinetic parameters (see Table 1). Fig. 1 shows repre- 
sentative pharmacokinetic profiles for two subjects. 
Data resulting from the intravenous yohimbine dose 
was fit to a two-compartment open model in all seven sub- 
jects. The C~iv was high (mean 7.38 (5.91) h-l),  signifying a 
very rapid distribution tl/2a of approximately 6 min. The 
elimination tu2p was also very rapid, 0.68 h (mean ~iv, 1.02 
(0.29) h- l ) .  The volume of distribution (Vc) was rather 
small (mean 0.26 (0.12) 1. kg- 1) and the CLiv ranged from 
2.44 to 15.8 ml. min - 1. kg - ~ (mean 9.77 (4.46) ml. min- 1. 
kg-~). 
Data resulting from the oral yohimbine dose was fit to 
either a one- (3 subjects) or two-compartment (4 sub- 
jects) pharmacokinetic model with a first order absorp- 
tion rate c o n s t a n t  (ka). The ka varied from 5.0 to 14.3 h-1 
(mean 6.22 (4.71) h-1), resulting in a mean absorption t1/2 
of approximately 7 min. The peak plasma concentration 
usually occurred within 10 to 45 min following administra- 
tion. In the three subjects in which O9o could be deter- 
mined, the mean was 8.87 h -1 (ranging from 1.34 to 
16.1 h-l);  these values were similar to those following the 
intravenous dose suggesting an extremely rapid distribu- 
tion of the drug. The mean oral tl/2~ was 0.58 h (mean [3po 
T a b l e  L Intravenous and oral yohimbine pharmacokinetic values 
Oral 
Subject AUC CL (ml- rain- 7. kg- 1) Vz (1. kg- 1 )  
1 10.7 200 10.6 
2 656 2.82 0.27 
3 45.1 42.2 4.32 
4 54.3 32.4 0.51 
5 56.7 37.8 1.43 
6 52.9 38.1 3.56 
7 61.8 37.1 1.89 
Mean 134 55.9 3.22 
(SD) (231) (65.1) (3.57) 
Intravenous 
AUC CL (ml-min- l .kg  -z ) Vc (1.kg -1 ) f 
150 14.2 0.39 0.071 
755 2.44 0.11 0.869 
121 15.8 0.31 0.374 
206 8.53 0.19 0.263 
202 10.6 0.23 0.280 
203 9.93 0.18 0.261 
331 6.93 0.43 0.187 
281 9.77 0.26 0.33 
(219) (4.46) (0.12) (0.26) 
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of 1.19 (0.42)h-1). The CLpo ranged from 2.81 to 
200 ml .min - l -kg  -I (mean 55.9 ml.min -~ .kg -~) and Vc 
was 3.22 (3.57) 1. kg- 1. 
The AUCiv ranged from 121 to 755 ng. ml 1. h (mean 
281 (219) ng .ml  1. h). The AUCpo showed even greater 
variability, ranging from 10.7 to 657 ng. ml-  1. h (mean 134 
(231)). The f ranged from 0.07 to 0.87 (mean f was 0.33 
(0.26)), which suggests that the average oral bioavaila- 
bility of yohimbine is only about 30% of the dose adminis- 
tered. 
Although blood pressure and heart  rate both in- 
creased following yohimbine, the increment of increase 
was variable. None of the incremental increases were 
correlated with yohimbine plasma concentration, except 
the systolic blood pressure which correlated weakly 
(r = 0.35, P < 0.005) with yohimbine plasma concentration 
following intravenous dosing. 
uals that respond more robustly to a yohimbine infusion 
than the general population [7, 8]. Alternatively, it is 
possible that yohimbine has a pharmacologically active 
metabolite that interferes with the parent drug's pharma- 
codynamic activity and results in differing responses that 
are correlated with the concentrations of both the parent 
drug and the metabolite. 
The results of this study indicate that the oral bioavai- 
lability of yohimbine is quite variable and it can be ex- 
pected that considerable individualization of dosing may 
be necessary when the drug is used orally for clinical indi- 
cations. Also, when yohimbine is utilized as an 0~2 adreno- 
ceptor probe or a drug challenge, it would be preferable to 
administer it intravenously, since oral bioavailability is not 
reliable. 
Discussion and conclusions 
The results of this study indicate that the oral bioavaila- 
bility of yohimbine is highly variable. Although it aver- 
ages approximately 30% it may vary from less than 10% to 
almost 90%. This may be significant since yohimbine is 
generally administered orally. It is possible that in some 
cases its lack of efficacy in the treatment of impotence or 
its inability to initiate a panic attack in a patient with panic 
disorder may be due to limited oral bioavailability. 
Clearance, like bioavailability, showed a great amount  
of interpatient variability. One subject exhibited both an 
extremely slow clearance of the drug and the greatest 
bioavailability (89%). Unfortunately, the metabolic steps 
involved in the biotransformation of yohimbine in hu- 
mans are currently unknown. Owen et al. [10] have shown 
that only a small proportion of yohimbine is eliminated 
unchanged in the urine, therefore the majority of the drug 
is probably biotransformed. Clearance values following 
intravenous administration are generally high and com- 
patible with liver blood flow in many cases. This suggests 
that its decreased bioavailability is due to drug extraction 
in the liver, although decreased intestinal absorption can- 
not be excluded at this point. 
Many of our findings are in agreement with those pre- 
viously reported [10]. The Vziv is smaller than expected for 
a drug that is highly lipophilic. Several of our subjects re- 
ported symptoms that were consistent with central nerv- 
ous system effects, usually within about 30 min of drug ad- 
ministration, which would indicate that the drug quickly 
crosses the blood brain barrier. 
Changes in diastolic blood pressure and heart  rate fol- 
lowing yohimbine did not correlate directly with plasma 
concentrations, although changes in general were larger 
following intravenous doses. Systolic blood pressure did 
correlate weakly with plasma yohimbine concentration 
following intravenous injection. Yohimbine-evoked 
pressor response is probably only slightly correlated with 
plasma yohimbine concentration because of the con- 
founding effect of the specific adrenomedullary activity of 
the individual patient. The results of two yohimbine chal- 
lenge studies suggest that there are subgroups of individ- 
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